Protein kinase C-α mediates epidermal growth factor receptor transactivation in human prostate cancer cells
- 1 May 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 4 (5), 726-732
- https://doi.org/10.1158/1535-7163.mct-05-0013
Abstract
Progression of human prostate cancer to a malignancy that is refractory to androgen-ablation therapy renders the disease resistant to available treatment options and accounts for the high prostate cancer mortality rate. Epidermal growth factor receptor (EGFR) expression in human prostate cancer specimens increases with disease progression to androgen-refractory prostate cancer, and experimental models implicate EGFR-dependent signaling to Erk1/2 activation in the androgen-refractory prostate cancer phenotype. 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced Erk1/2 activation in human prostate cancer PC-3 cells is a paradigm of diacylglycerol-induced EGFR transactivation in androgen-independent prostate cancer. In this report, we establish an obligatory role for TPA-induced protein kinase C (PKC)-α activation in EGFR transactivation and signaling to Erk1/2 activation in PC-3 cells. TPA-regulated molecules include PKCs, PKDs, and Ras guanyl nucleotide-releasing proteins. The PKC-selective inhibitors GF109203X and Gö6983 each blocked TPA-induced EGFR transactivation, indicating a requirement for PKC. PC-3 cells express four PKC isozymes. Prolonged bryostatin 1 treatment abrogated PKCα expression without altering expression levels of the other PKC isozymes. Pharmacologic PKCα “knockdown” abrogated TPA-induced Erk1/2 activation without affecting the EGF/EGFR-induced response, indicating that PKCα was required for EGFR transactivation but dispensable for signaling of ligand-activated EGFR to Erk1/2 activation. We corroborated this by showing that Gö6976, which is a PKCα-selective inhibitor in PC-3 cells, likewise abolished TPA-induced Erk1/2 activation and did not inhibit EGF/EGFR-induced Erk1/2 activation. Gö6976 had similar effects in DU145 cells, providing evidence for a common PKCα-dependent Erk1/2 activation mechanism in androgen-independent human prostate cancer cells of distinct genetic origin. These results constitute a rational basis for selective PKCα inhibition as a modality of prostate cancer therapy.Keywords
This publication has 32 references indexed in Scilit:
- Phorbol Ester-induced Apoptosis of C4-2 Cells Requires Both a Unique and a Redundant Protein Kinase C Signaling PathwayJournal of Biological Chemistry, 2005
- ADAM Binding Protein Eve-1 Is Required for Ectodomain Shedding of Epidermal Growth Factor Receptor LigandsPublished by Elsevier BV ,2004
- Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate CancerClinical Cancer Research, 2004
- Protein Kinase C Promotes Apoptosis in LNCaP Prostate Cancer Cells through Activation of p38 MAPK and Inhibition of the Akt Survival PathwayPublished by Elsevier BV ,2003
- Foundation for the integration of biologically based therapy in the management of prostate cancerThe Prostate, 2003
- Transactivation of the Epidermal Growth Factor Receptor Is Involved in 12-O-Tetradecanoylphorbol-13-acetate-induced Signal TransductionPublished by Elsevier BV ,2001
- Protein Kinase C Isoenzyme Patterns Characteristically Modulated in Early Prostate CancerThe American Journal of Pathology, 1999
- Increased concentrations of phosphatidate, diacylglycerol and ceramide in ras- and tyrosine kinase (fps)-transformed fibroblastsOncogene, 1997
- Inhibition of protein kinase C μ by various inhibitors. Inhibition from protein kinase c isoenzymesFEBS Letters, 1996
- Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition.The Journal of cell biology, 1995